Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914840 | 0.90 | S1PR2 (0.38) | SMN1; SMN2LMNAALDH1A1S1PR2PTGS2 | |
| SCHEMBL23914661 | 0.88 | S1PR2 (0.37) | SMN1; SMN2LMNAALDH1A1S1PR2KDM4E | |
| SCHEMBL23908948 | 0.87 | NPC1 (0.42) | SMN1; SMN2LMNAALDH1A1S1PR2PTGS2 | |
| SCHEMBL23915526 | 0.84 | S1PR2 (0.46) | SMN1; SMN2LMNAALDH1A1S1PR2KDM4E | |
| SCHEMBL23914498 | 0.79 | KDM4E (0.41) | SMN1; SMN2LMNAALDH1A1S1PR2KDM4E | |
| SCHEMBL23914832 | 0.79 | ALDH1A1 (0.36) | SMN1; SMN2LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL23915425 | 0.78 | S1PR2 (0.36) | SMN1; SMN2LMNAALDH1A1S1PR2KDM4E | |
| SCHEMBL23914597 | 0.78 | ALDH1A1 (0.35) | SMN1; SMN2LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL23914841 | 0.78 | NPC1 (0.42) | SMN1; SMN2LMNAALDH1A1S1PR2KDM4E | |
| SCHEMBL23914490 | 0.77 | MAPT (0.44) | S1PR2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885LMNA 449/4885ALDH1A1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.